Back to News
Market Impact: 0.35
Mesoblast H2 Earnings Call Highlights
Source: marketbeat.com
Company FundamentalsHealthcare & BiotechRegulation & LegislationCorporate Earnings
Mesoblast (MESO) reported $115M in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL. The FDA-approved therapy is for children with steroid-refractory acute GVHD. This revenue debut supports commercialization traction and is a positive fundamental update for the company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MESO0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos